SG11202003840QA - Composition for controlled ovarian stimulation - Google Patents

Composition for controlled ovarian stimulation

Info

Publication number
SG11202003840QA
SG11202003840QA SG11202003840QA SG11202003840QA SG11202003840QA SG 11202003840Q A SG11202003840Q A SG 11202003840QA SG 11202003840Q A SG11202003840Q A SG 11202003840QA SG 11202003840Q A SG11202003840Q A SG 11202003840QA SG 11202003840Q A SG11202003840Q A SG 11202003840QA
Authority
SG
Singapore
Prior art keywords
composition
ovarian stimulation
controlled ovarian
controlled
stimulation
Prior art date
Application number
SG11202003840QA
Inventor
Saez Joan-Carles Arce
Lisbeth Helmgaard
Bjarke Mirner Klein
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of SG11202003840QA publication Critical patent/SG11202003840QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202003840QA 2017-09-01 2018-08-31 Composition for controlled ovarian stimulation SG11202003840QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (en) 2017-09-01 2018-08-31 Composition for controlled ovarian stimulation

Publications (1)

Publication Number Publication Date
SG11202003840QA true SG11202003840QA (en) 2020-05-28

Family

ID=59772482

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003840QA SG11202003840QA (en) 2017-09-01 2018-08-31 Composition for controlled ovarian stimulation

Country Status (30)

Country Link
US (2) US11744879B2 (en)
EP (2) EP3675894B1 (en)
JP (2) JP6856819B2 (en)
KR (1) KR20200045543A (en)
CN (1) CN111050787A (en)
AR (1) AR112541A1 (en)
AU (1) AU2018326556A1 (en)
BR (1) BR112020003379A2 (en)
CA (1) CA3073624A1 (en)
CL (1) CL2020000482A1 (en)
DK (1) DK3675894T3 (en)
EA (1) EA202090480A1 (en)
ES (1) ES2904787T3 (en)
HR (1) HRP20211802T1 (en)
HU (1) HUE056726T2 (en)
IL (1) IL272763B2 (en)
JO (1) JOP20200034A1 (en)
LT (1) LT3675894T (en)
MA (2) MA50034B1 (en)
MD (1) MD3675894T2 (en)
MX (1) MX2020002235A (en)
PH (1) PH12020500404A1 (en)
PL (1) PL3675894T3 (en)
PT (1) PT3675894T (en)
RS (1) RS62810B1 (en)
SG (1) SG11202003840QA (en)
SI (1) SI3675894T1 (en)
TW (1) TWI749255B (en)
UA (1) UA126869C2 (en)
WO (1) WO2019043143A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237173A (en) * 2020-12-09 2022-10-01 荷蘭商菲林公司 Compositions and methods for controlled ovarian stimulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0107881A (en) * 2000-01-27 2003-04-01 Applied Research Systems Fsh use infertility treatment
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
ES2494928T3 (en) * 2007-09-21 2014-09-16 Pharmabrand S.A. Composition comprising mucilaginous polysaccharides derived from Aloe barbadensis combined with liposomes, method for obtaining them and their use as sunscreen, an anti-acne agent, an epidermal regenerator and a moisturizer
TWI488640B (en) 2008-04-16 2015-06-21 Ferring Int Ct Sa Pharmaceutical preparation
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
AR090095A1 (en) 2011-06-06 2014-10-22 Ferring Bv PHARMACEUTICAL PREPARATION THAT INCLUDES STIMULATING HORMONE OF THE RECOMBINANT FOLICLE
JO3092B1 (en) 2011-08-08 2017-03-15 Ferring Bv Composition for controlled ovarian stimulation
SG11201608132UA (en) * 2014-04-18 2016-11-29 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone
PL3261661T3 (en) 2015-02-26 2024-03-25 Ferring B.V. Menotropin for treating infertility
SI3662925T1 (en) 2015-04-17 2021-08-31 Ferring B.V. Composition comprising fsh for treatment of infertility
LT3286209T (en) 2015-04-24 2021-02-25 Ferring Bv Method of production of gonadotrophin
KR20180020982A (en) 2015-06-26 2018-02-28 훼링 비.브이. Purification method and / or virus inactivation treatment method
JP2021522268A (en) 2018-04-30 2021-08-30 フェリング ベスローテン フェンノートシャップ Composition for controlled ovarian stimulation
CA3110205A1 (en) 2018-10-17 2020-04-23 Ferring Bv Compositions and methods for controlled ovarian stimulation

Also Published As

Publication number Publication date
JP7373479B2 (en) 2023-11-02
MA50034B1 (en) 2022-02-28
ES2904787T3 (en) 2022-04-06
JP6856819B2 (en) 2021-04-14
TW201919687A (en) 2019-06-01
MD3675894T2 (en) 2022-03-31
US11744879B2 (en) 2023-09-05
US20240024424A1 (en) 2024-01-25
US20200197493A1 (en) 2020-06-25
JP2021046398A (en) 2021-03-25
IL272763A (en) 2020-04-30
WO2019043143A1 (en) 2019-03-07
BR112020003379A2 (en) 2020-08-25
KR20200045543A (en) 2020-05-04
LT3675894T (en) 2021-12-10
PL3675894T3 (en) 2022-02-21
HUE056726T2 (en) 2022-03-28
CN111050787A (en) 2020-04-21
SI3675894T1 (en) 2022-01-31
DK3675894T3 (en) 2022-01-24
AR112541A1 (en) 2019-11-06
EP3675894A1 (en) 2020-07-08
EP3675894B1 (en) 2021-11-03
HRP20211802T1 (en) 2022-03-04
EP3973982B1 (en) 2024-07-31
MX2020002235A (en) 2020-07-20
TWI749255B (en) 2021-12-11
EP3973982A1 (en) 2022-03-30
MA56224A (en) 2022-04-20
PH12020500404A1 (en) 2021-03-01
IL272763B2 (en) 2024-02-01
JOP20200034A1 (en) 2020-02-13
PT3675894T (en) 2022-01-25
CA3073624A1 (en) 2019-03-07
RS62810B1 (en) 2022-02-28
UA126869C2 (en) 2023-02-15
EA202090480A1 (en) 2020-07-20
IL272763B1 (en) 2023-10-01
MA50034A (en) 2021-05-12
JP2020528071A (en) 2020-09-17
AU2018326556A1 (en) 2020-03-05
CL2020000482A1 (en) 2020-06-26

Similar Documents

Publication Publication Date Title
ZA202002723B (en) Composition
GB201703455D0 (en) Composition
GB2562466B (en) Composition
GB201719139D0 (en) Composition
GB201700504D0 (en) Composition
GB201713636D0 (en) Composition
GB201712151D0 (en) Composition
GB201707238D0 (en) Composition
EP3675653C0 (en) Antimycotoxin composition
IL272763A (en) Composition for controlled ovarian stimulation
GB201721674D0 (en) Composition
IL280750A (en) Compositions and methods for controlled ovarian stimulation
GB201702833D0 (en) Composition
GB201816988D0 (en) Composition
RS64676B1 (en) Probiotical composition
SG11201903852WA (en) Composition for activating sympathetic nerve
GB201718871D0 (en) Composition
GB201715135D0 (en) Composition
GB201711446D0 (en) Composition
GB201707920D0 (en) Composition
ZA201904385B (en) Composition
PL3576546T3 (en) Probiotical composition
GB201721675D0 (en) Composition
GB201719763D0 (en) Composition
GB201719456D0 (en) Composition